Cardiovascular effects of levodopa.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D001281:Atrial Fibrillation / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006321:Heart / Q000187:drug effects*; D006352:Heart Ventricles; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007511:Ischemia / Q000139:chemically induced; D007668:Kidney / Q000187:drug effects; D008750:Methyldopa / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D013268:Stimulation, Chemical; D013610:Tachycardia / Q000139:chemically induced
D018492:Dopamine Antagonists; D010643:Phenoxybenzamine; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D011433:Propranolol; D004298:Dopamine; D010646:Phentolamine